Remicade strong for Mitsubishi Tanabe but albumin fallout clouds outlook
This article was originally published in Scrip
Executive Summary
Another strong performance from Remicade was not enough to halt a decline in sales at Japan's Mitsubishi Tanabe Pharma (MTP) in the year to 31 March.